Scholars Central

Conference abstractPublished 18 Oct 2017

Tumor genomic sequencing to guide treatment

Authors: George Vasmatzise

Mayo Clinic, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Identification of key genetic mutations in tumors can be exploited to prescribe treatments specifically targeted to those mutations. Tumors harbor many mutations/rearrangements, and it is not clear which mutation or combination of mutations is most critical. We have developed an integrated approach that combines genomic analytics and experimental validation to provide precise treatment options to patients that fail standard of care. Tumors are interrogated by a combination of MPseq, RNAseq and WES. MPseq is a process that provides a detailed description of all DNA rearrangements at a resolution that can show how individual genes are disturbed thus providing necessary novel insight for correct clinical interpretation. The potential detection of targetable rearrangements and mutations cross-validated by RNAseq provides relatively robust evidence that the associated pathways are targetable. Related drugs can then be validated experimentally in 3D-culture model systems, termed microtumors. The combination of the above processes could provide reasonable indication to oncologists to act.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectGenetics & Molecular Biology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “George Vasmatzise”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels